More than 70% solid tumor cure rate! The anti-CTLA-4 antibody of the tumor bovine pox virus will be clinical trials at the end of the year.

Recently, transgene and bioinvent international AB, which focus on the design and development of virus-based immunotherapy to treat cancer, have released the preclinical data of bt-001, which is equipped with anti CTLA-4 antibody, which proves that bt-001 has a strong potential in solid tumors. The specific data will be displayed in AACR online conference.in the press release, the two companies have completed the preclinical concept verification of bt-001: in a variety of solid tumor mouse models, the cure rate of bt-001 is more than 70%, which proves that bt-001 has a strong therapeutic effect as a single drug, which lays a solid foundation for the next clinical development of bt-001, and is expected to conduct clinical trials by the end of 2020.clinical data validation bt-001 is based on the proprietary technology platform of transgene Invir.IO Gamma The new oncolytic virus, vaccinia virus, has been engineered to bind to tumor cells and produce anti CTLA-4 antibody and GM-CSF in the tumor area. At the same time, it can also target the tumor microenvironment and generate immune response to tumor cells.bt-001 anti CTLA-4 antibody and GM-CSF accumulated locally in the form of low systemic exposure.in xenograft tumor model, the anti CTLA-4 antibody in tumor was 10 times higher than that after intraperitoneal injection of 3 mg / kg recombinant antibody.the cure rate of bt-001 was more than 70% in various solid tumor mouse models.the tumor cells were implanted into the mouse model which was cured after the first treatment of bt-001, and the mice had strong tumor specific response and persistent immune memory.is considered to be useful in preventing tumor recurrence.at present, bt-001 is in the clinical preparation stage, and the company expects to enter the clinical trial by the end of this year.pioneer of viral genome engineering: transgenetransgene (Euronext: TNG) is a publicly listed French biotechnology company focusing on the design and development of targeted immunotherapy for cancer and infectious diseases.transgene integrates gene sequences into viral vectors, which can indirectly or directly kill infected or cancer cells.these immunotherapies can be used alone or in combination with other therapies (immunotherapy, chemotherapy, etc.).the company's major clinical phase plans are: tg4001, a therapeutic vaccine for HPV positive head and neck cancer; tg6002, a oncolytic virus for solid tumors; and tg4050, a personalized therapeutic vaccine based on the myvac platform.transgene's R & D pipeline has developed two platforms: Invir.IO Gamma And myvac ™。Invir.IO Gamma The new oncolytic virus designed and produced can regulate the tumor microenvironment, thus showing improved antitumor activity; the platform has produced several preclinical evaluation candidates, including bt-001.in addition, on May 2, 2019, transgene announced that it had signed a cooperation and exclusive license agreement with AstraZeneca to use the next generation virus platform exclusively owned by transgene Invir.IO Gamma Five new types of armed oncolytic vaccinia viruses were jointly developed.myvac Gamma Tg4050 is a personalized immunotherapy platform based on MVA, which aims to integrate new antigens and improve this innovative research portfolio. Tg4050 developed in cooperation with NEC is based on myvac Gamma The first product candidate for.tg4050 is currently conducting two phase 1 clinical trials for ovarian cancer and head and neck cancer.transgene has been conducting business in China through TESL chuangshijie since 2010, and now TSL biomedical has 100% control of TSG.on April 18, 2019, Tianshi chuangshijie (Tianjin) biopharmaceuticals received the drug clinical trial notice of recombinant oncolytic vaccinia virus injection T601 (foreign code: tg6002) approved and issued by the State Food and drug administration.conclusion: the emergence of new oncolytic viruses, such as measles virus, vaccinia virus, poliovirus, as well as redesigned viruses and new treatment strategies, give new hope to human beings to conquer tumors, and the company's oncolytic virus strategy may bring new surprises.with the further understanding of the biological characteristics of various oncolytic viruses and the in-depth study of anti-tumor mechanisms, we believe that oncolytic viruses will be more useful in potential indications in the near future! Reference: 1